UNASSIGNED: We sought to detect additional underlying hair loss disorders in patients with postpartum telogen effluvium.
UNASSIGNED: We completed clinical and dermoscopic evaluations on 200 female participants experiencing postpartum hair loss.
UNASSIGNED: 9.5 percent of patients were diagnosed with telogen effluvium (TE), 56.0 percent patients were diagnosed with TE with androgenetic alopecia (AGA), 6.5 percent patients were diagnosed with TE and TA, and 28.0 percent patients were diagnosed with TE, AGA, and TA. In the central area, patients with TE displayed upright regrowing hair and single pilosebaceous unit in 100 percent and 94.7 percent of patients, respectively. While patients with TE and AGA, displayed upright regrowing hair, single pilosebaceous unit, and hair diameter diversity greater than 20 percent. In patients diagnosed with TE and TA, the trichoscopic findings were similar in the TE group to the patients diagnosed with TE, AGA, and TA were also similar to the patients with TE and AGA. Regarding the area of traction, there was no difference observed between the patients with TE and TA and patients with TE, AGA, and TA. The frequent findings were hair diameter diversity, empty follicles, and vellus hair.
UNASSIGNED: Postpartum TE may be associated with other hair loss disorders. Awareness of this is critical to appropriate diagnosis and treatment.

UNASSIGNED: Androgenetic alopecia leads to progressive hair loss in susceptible individuals if left untreated. Topical minoxidil represents an evidence-based treatment for female androgenetic alopecia, though with variable success.
UNASSIGNED: Treatment of minoxidil non-responders remains challenging, as does treatment of patients with propylene glycol sensitivity or irritable scalp syndrome.
UNASSIGNED: Single-center, retrospective cohort of 50 female patients with androgenetic alopecia failing to respond to a minimum of 6 months of standard 5% topical minoxidil solution either once daily or b.i.d. depending on the severity of the alopecia. Patients were switched to propylene glycol-free, North American Witch Hazel (Hamamelis virginiana)-based solution of 5% minoxidil sulfate (5% minoxidil sensitive solution). Efficacy and safety of treatment were evaluated, including stereotactic global photography and epiluminiscence microscopy with digital imaging taken at baseline, at 3, and at 6 months of treatment.
UNASSIGNED: 70% of patients showed observable clinical improvement with combined global photographic and epiluminiscence microscopic assessment with digital imaging, and 22% epiluminiscence microscopic-only improvement as evidence of treatment efficacy. The treatment was well tolerated, particularly in patients with propylene glycol sensitivity and patients with irritable scalp syndrome.
UNASSIGNED: These results suggest that propylene glycol-free, North American witch hazel (Hamamelis virginiana)-based solution of 5% minoxidil is effective and safe for treatment of female androgenetic alopecia, specifically in minoxidil non-responders and patients with propylene glycol sensitivity or irritable scalp syndrome.

UNASSIGNED: Cumulative evidence suggests the involvement of the occipital region in female pattern hair loss (FPHL). However, most of the studies that have been published so far concerned relatively small samples of patients.
UNASSIGNED: To assess the occipital involvement in FPHL and analyze its correlation with disease severity among a large sample of patients.
UNASSIGNED: A retrospective study involved 1000 adult women with FPHL, between January 2020 and August 2022. Occipital involvement was defined as more than 10% of thin hairs (<0.03 mm). Baseline trichometry parameters in the frontal and occipital regions were analyzed.
UNASSIGNED: Occipital involvement was observed in 32.4% of the patients. Positive correlations between frontal and occipital regions were observed for all trichometry parameters; the strongest concerned average hair shaft thickness (Pearson\'s coefficient r=0.708), cumulative hair thickness (r=0.673), and trichometry-derived Sinclair scale (r=0.656). The risk of occipital involvement increased independently with the disease severity in frontal region; however, the disease progression was slower in the occipital compared to frontal region.
UNASSIGNED: One-third of females in our study with FPHL had occipital involvement. This has a major impact on the methods used to diagnose pattern hair loss in females and their treatment plan including hair restoration surgery.

BACKGROUND: Female androgenetic alopecia (FAGA) is a condition that affects women and involves the gradual loss of terminal hair in specific areas of the scalp. The limited treatment options for FAGA necessitate the development of new strategies. This study aimed to evaluate the potential benefit of using a combination therapy composed of autologous platelet-rich plasma (PRP) and a non-cross-linked hyaluronic acid (HA) compound in the treatment of FAGA.
METHODS: This was a retrospective, case-series study, which enrolled nine female patients with FAGA between September 2021 and December 2022. The non-cross-linked HA compound (Hearty®, Imeik Technology Development Co., Ltd.) and PRP were implanted into the areas of hair loss over four treatment sessions separated by 4-week intervals. Patients were monitored for overall improvement in their hair loss, hair count, treatment satisfaction, and adverse events at 1, 3, and 6 months follow-up.
RESULTS: The improvement rates, subjectively evaluated by the study physician, were 88.89% at the 1-month and 100% at the 3-month follow-up, relative to baseline. Moreover, the quantitative evaluation results showed that the FAGA patients\' hair density increased by 54.51% at the 1-month and by 77.25% at the 3-month follow-up.
CONCLUSIONS: The combination of PRP and non-cross-linked HA compound appeared to be a certain positive effective procedure for FAGA without serious adverse event. We envisage that this work will contribute to the development of new treatment options for women suffering from this condition.

暂无摘要。

UNASSIGNED: Female androgenetic alopecia (FAGA) is a patterned hair loss caused by progressive miniaturization of hair follicles. This leads to reduction in the number and thickness of hairs, especially in the central, frontal, and parietal scalp regions. Telogen effluvium (TE) is characterized by diffuse hair loss within months of a significant systemic stressor because of premature follicular transition from the anagen to the telogen.
UNASSIGNED: This article aims to highlight the dermoscopic differences between TE and FAGA compared to healthy female controls.
UNASSIGNED: A total of 124 female patients, which included 31 women with clinical diagnosis of FAGA, 33 with TE, and 60 controls, were enrolled. Two dermatologists independently assessed each patient clinically as well as with dermoscope, recorded the history and examination findings on a proforma, and made a diagnosis. These dermoscopic images were later revised in photographs on the computer.
UNASSIGNED: There was a statistically significant difference in hair diameter diversity (HDD) between patients with FAGA versus TE and FAGA versus controls (p<0.0001). The difference in the mean percentage of single PSU in both frontal and occipital areas in FAGA versus controls and FAGA versus TE patients was statistically significant. The vellus hair were significantly higher in the FAGA patients than TE and control.
UNASSIGNED: Dermoscopic features of FAGA and TE will help in early detection on the basis of increased proportion of thin and vellus hairs, HDD, perifollicular discoloration, and the presence of a variable number of yellow dots.

BACKGROUND: The number of clinical trials evaluating platelet-rich plasma (PRP) efficacy in female androgenetic alopecia (F-AGA) has exponentially increased during the last five years. A systematic review focused on this specific field has been performed by assessing the local infiltrations of PRP compared with any control for F-AGA in the selected studies.
OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of the use of PRP in F-AGA.
METHODS: The protocol was developed in accordance with the Preferred Reporting for Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines. A multistep search of PubMed, MEDLINE, Embase, PreMEDLINE, Ebase, CINAHL, PsycINFO, Clinicaltrials.gov, Scopus database, and Cochrane databases has been performed to identify papers on female pattern hair loss (FPHL) treatment with PRP. Of the 63 articles initially identified, 11 articles focusing on AGA were selected and, consequently, only 5 articles focused exclusively on F-AGA were analyzed. Of this amount, 3 articles were randomized-controlled trials (RCTs), 1 clinical trial, and 1 double-blind placebo-controlled pilot study (DBPCPS). The studies included had to match predetermined criteria according to the PICOS (patients, intervention, comparator, outcomes, and study design) approach.
RESULTS: Eight percent of the articles selected and analyzed, reported a positive effect of PRP for F-AGA treatment. The information analyzed highlights the positive effects of PRP on F-AGA, without major side effects and thus, it may be considered as a safe and effective alternative procedure to treat hair loss compared with traditional drugs as Minoxidil® and Finasteride®.
CONCLUSIONS: The use of PRP in F-AGA was safe and effective for F-AGA.

Studies on androgenetic alopecia in Nigerian females are few. The aim of this study was to determine the prevalence of female androgenetic alopecia, its severity and trichoscopic features.
This was a cross-sectional descriptive study of androgenetic alopecia amongst 207 adult female traders at an urban market in Lagos, Nigeria. The study was conducted in February 2020. All recruited female traders were examined. Documentation of clinical findings, sociodemographic data and trichoscopy features was done using a predesigned questionnaire. Severity of female androgenetic alopecia was assessed using the Olsen\'s scale he IBM statistics software version 22.
The prevalence of female androgenetic alopecia (FAGA) was 4.8% (10/207) and median age of the participants was 59 (IQR 45,63) years. The severity of FAGA based on Olsen\'s scale was grade I, II and III in 30%, 20% and 50% respectively and severity increased with age. Trichoscopy features included prominent white dots (90%), reduced hair density (90%), vellus hairs (70%), preserved honeycomb pigment network (70%) and variable hair diameter (60%).
Androgenetic alopecia is uncommon in females. When present, it is noted to be severe. Trichoscopy features among African females in Nigeria are comparable to trichoscopy features in studies from other parts of the world.
Les études sur l\'alopécie androgénétique chez les femmes nigérianes sont peu nombreuses. Le but de cette étude était de déterminer la prévalence de l\'alopécie androgénétique féminine, sa gravité et ses caractéristiques trichoscopiques.
Il s\'agissait d\'une étude descriptive transversale de l\'alopécie androgénétique parmi 207 femmes adultes commerçantes sur un marché urbain de Lagos, au Nigeria. L\'étude a été menée en février 2020. Toutes les commerçantes recrutées ont été examinées. Les résultats cliniques, les données sociodémographiques et les caractéristiques de la trichoscopie ont été documentés à l\'aide d\'un questionnaire préétabli. La sévérité de l\'alopécie androgénétique féminine a été évaluée à l\'aide de l\'échelle d\'Olsen. Les données ont été analysées à l\'aide du logiciel de statistiques IBM version 22.
La prévalence de l\'alopécie androgénétique féminine (AAF) était de 4,8 % (10/207) et l\'âge médian des participants était de 59 ans (IQR 45,63). Selon l\'échelle d\'Olsen, la gravité de l\'alopécie androgénique féminine était de grade I, II et III dans 30 %, 20 % et 50 % des cas respectivement, et la gravité augmentait avec l\'âge. Les caractéristiques de la trichoscopie comprenaient des points blancs proéminents (90 %), une densité capillaire réduite (90 %), des poils vellus (70 %), un réseau pigmentaire en nid d\'abeille préservé (70 %) et un diamètre variable des poils (60 %).
L\'alopécie androgénétique est peu fréquente chez la femme. Lorsqu\'elle est présente, on note qu\'elle est sévère. Les caractéristiques de la trichoscopie chez les femmes africaines au Nigeria sont comparables aux caractéristiques de la trichoscopie dans les études d\'autres parties du monde.
Alopécie androgénétique féminine, Trichoscopie, Prévalence, Gravité, Gradation.

UNASSIGNED: This study aimed to explore the relationship between serum ferritin levels and telogen effluvium.
UNASSIGNED: A total of 193 telogen effluvium patients and 104 female androgenetic alopecia patients were included. We collected the test result of serum ferritin levels, compared with the results of 183 healthy subjects. Receiver Operator Characteristic curves were generated to assess the potential diagnostic value of serum ferritin in telogen effluvium patients.
UNASSIGNED: The serum ferritin in telogen effluvium patients were significantly lower than that in the healthy control group (P = 0.000) or female androgenetic alopecia patients (P =0.000). Patients with lower serum ferritin levels got high odds to have telogen effluvium. The areas under the Receiver Operator Characteristic curve of serum ferritin levels were 0.735 and 0.645 for distinguishing telogen effluvium patients from healthy control subjects or female androgenetic alopecia patients.
UNASSIGNED: Serum ferritin could be a potential biomarker for clinical diagnosis of telogen effluvium.

Female androgenetic alopecia (FAGA) is a common cause of hair loss in women. Typically, it is characterized by a reduction of hair density on biparietal and vertex regions of the scalp with preservation of the anterior hair implantation line. However, it can also appear with recession of the anterior hairline known as FAGA with male pattern (FAGA-M). In these cases, it is important to consider a state of hyperandrogenism and look for other signs such as hirsutism, acne, and menstrual irregularities. A sudden onset in a postmenopausal woman must make us suspicious of an androgen-secreting tumor. We present two cases of FAGA-M secondary to an ovarian tumor that was successfully resolved after surgical treatment.